Search
Agmatine
go.drugbank.com/drugs/DB08838ExperimentalUp to now (July 2013), the results of this study have not yet been published. … It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges, and the mammalian brain.
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedIt is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography [FDA Label]. … Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalThe main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.
SGS-742
go.drugbank.com/drugs/DB05010InvestigationalSGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedSulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. … It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.
Ritiometan
go.drugbank.com/drugs/DB13267ApprovedRitiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … [A244170, A244175, A244180, A244190] Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalAlthough it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.